1. Report Introduction 2. Amyotrophic lateral sclerosis (ALS) Market Overview at a Glance 2.1. Market Share Distribution of Amyotrophic lateral sclerosis (ALS) in 2016 2.2. Market Share Distribution of Amyotrophic lateral sclerosis (ALS) in 2028 3. Disease Background and Overview: Amyotrophic lateral sclerosis (ALS) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Amyotrophic lateral sclerosis (ALS) in 7MM 4.3. Total Prevalent Patient Population of Amyotrophic lateral sclerosis (ALS) in 7MM – By Countries 5. Epidemiology of Amyotrophic lateral sclerosis (ALS) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) 5.1.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) * 5.1.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) * 5.1.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) 5.1.6. Treatable Cases of the Amyotrophic lateral sclerosis (ALS) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) 5.4.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) * 5.4.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) * 5.4.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) 5.4.6. Treatable Cases of the Amyotrophic lateral sclerosis (ALS) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) 5.5.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) * 5.5.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) * 5.5.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) 5.5.6. Treatable Cases of the Amyotrophic lateral sclerosis (ALS) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) 5.6.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) * 5.6.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) * 5.6.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) 5.6.6. Treatable Cases of the Amyotrophic lateral sclerosis (ALS) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) 5.7.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) * 5.7.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) * 5.7.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) 5.7.6. Treatable Cases of the Amyotrophic lateral sclerosis (ALS) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) 5.8.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) * 5.8.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) * 5.8.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) 5.8.6. Treatable Cases of the Amyotrophic lateral sclerosis (ALS) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) 5.9.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) * 5.9.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) * 5.9.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) 5.9.6. Treatable Cases of the Amyotrophic lateral sclerosis (ALS) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Amyotrophic lateral sclerosis (ALS) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Amyotrophic lateral sclerosis (ALS) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Amyotrophic lateral sclerosis (ALS) : 7MM Market Analysis 12.1. 7MM Market Size of Amyotrophic lateral sclerosis (ALS) 12.2. 7MM Percentage Share of drugs marketed for Amyotrophic lateral sclerosis (ALS) 12.3. 7MM Market Sales of Amyotrophic lateral sclerosis (ALS) by Products 13. Amyotrophic lateral sclerosis (ALS) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Amyotrophic lateral sclerosis (ALS) in United States 13.1.2. Percentage Share of drugs marketed for Amyotrophic lateral sclerosis (ALS) in United States 13.1.3. Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Amyotrophic lateral sclerosis (ALS) in Germany 13.2.1.2. Percentage Share of drugs marketed for Amyotrophic lateral sclerosis (ALS) in Germany 13.2.1.3. Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Amyotrophic lateral sclerosis (ALS) in France 13.2.2.2. Percentage Share of drugs marketed for Amyotrophic lateral sclerosis (ALS) in France 13.2.2.3. Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Amyotrophic lateral sclerosis (ALS) in Italy 13.2.3.2. Percentage Share of drugs marketed for Amyotrophic lateral sclerosis (ALS) in Italy 13.2.3.3. Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Amyotrophic lateral sclerosis (ALS) in Spain 13.2.4.2. Percentage Share of drugs marketed for Amyotrophic lateral sclerosis (ALS) in Spain 13.2.4.3. Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Amyotrophic lateral sclerosis (ALS) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Amyotrophic lateral sclerosis (ALS) in United Kingdom 13.2.5.3. Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Amyotrophic lateral sclerosis (ALS) in Japan 13.3.2. Percentage Share of drugs marketed for Amyotrophic lateral sclerosis (ALS) in Japan 13.3.3. Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in 7MM Table 2: Total Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028) Table 5: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028) Table 6: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028) Table 7: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) Table 11: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) Table 12: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) Table 14: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) Table 15: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) Table 16: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) Table 17: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) Table 21: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) Table 22: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) Table 26: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) Table 27: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) Table 30: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) Table 31: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) Table 32: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) Table 36: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) Table 37: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Table 42:7MM- Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Table 45: United States-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Table 48: Germany-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Table 51: France-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Table 54: Italy-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Table 57: Spain-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Table 60:UK-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Table 63: Japan-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in 7MM Figure 2: Total Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028) Figure 6: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028) Figure 7: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) Figure 12: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) Figure 15: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) Figure 16: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) Figure 17: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) Figure 22: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) Figure 27: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) Figure 31: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) Figure 32: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) Figure 37: Treatable Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Figure 42:7MM- Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Figure 45: United States-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Figure 48: Germany-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Figure 51: France-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Figure 54: Italy-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Figure 57: Spain-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Figure 60:UK-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Amyotrophic lateral sclerosis (ALS) in USD MM (2016-2028) Figure 63: Japan-Market Share Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Amyotrophic lateral sclerosis (ALS) by Therapies in USD MM (2016-2028)